Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2026. The document serves as a transaction notification regarding a purchase of company securities by a Principal Director or Manager (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to a specific insider transaction.
| Metric | Value |
|---|---|
| Transaction Price | $50.6400 |
| Transaction Volume | 9.4289 ADS |
| Instrument | American Depositary Shares (ADS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an acquisition of notional ADS within the GSK Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of an insider trade executed on June 8, 2026, on the New York Stock Exchange.
Investor Verification Points
- Verify the identity of the PDMR: Maya Martinez-Davis, President, US.
- Confirm the transaction date: June 8, 2026.
- Note that the transaction was an acquisition within a supplemental savings plan, not an open market purchase.
- Check the LEI for GSK plc: 5493000HZTVUYLO1D793.